Medical insurance reimbursement conditions and reimbursement ratios for bedaquiline fumarate (Snaery)

Bedaquiline fumarate (Bedaquiline) is a new anti-tuberculosis drug that is considered a major breakthrough in the treatment of tuberculosis in recent years. Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis, has long been a global health problem. However, traditional TB treatment regimens often require long-term use of multiple drugs and are prone to drug resistance, leading to an urgent need for new treatments.

Bedaquiline (Sneril) reimbursement is limited to: patients with multidrug-resistant tuberculosis. Bedaquiline (Sneril) has now been launched in the domestic market and has also been included in the coverage of medical insurance. It belongs to Class B medical insurance (the reimbursement ratio is around 70%), and patients can purchase it in the hospital. Each box contains 100mg*24 tablets and is priced in the range of four to five thousand yuan. However, please note that specific prices and medical insurance reimbursement details need to be consulted with the local hospital pharmacy to obtain the most accurate information.

In addition, if you are looking for a more economical option, the Russian version of the original drug is a good option. Its specifications are 100mg*188 tablets, and the price is only more than 10,000 yuan, which is significantly more affordable than the domestic version. It is worth mentioning that this Russian version of the drug is the same original drug as the domestic bedaquiline (Sneril), so there is no difference in therapeutic effect.

Bedaquiline (Snaery), as a revolutionary drug, was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of drug-resistant tuberculosis. It is a drug that targets ATP synthase and treats the disease by inhibiting the growth of Mycobacterium tuberculosis. Compared with traditional anti-tuberculosis drugs, bedaquiline (Sneril) has higher selectivity and faster bactericidal rate, making it an effective option for the treatment of multidrug-resistant (MDR) tuberculosis.

Although bedaquiline (Snaery) has shown significant effectiveness in treating drug-resistant TB, it is not the only answer to the TB problem. The control of tuberculosis also requires comprehensive prevention and control measures, including timely diagnosis, standardized treatment, and strengthened monitoring. In addition, continued investment in drug research and development is needed to find more new anti-tuberculosis drugs, especially treatments for drug-resistant strains.